NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (379)	2/5/1999 8:56:00 AM
From: LLCF	of 613

WSJ "B" section has articles on "stroke treatment" (Abbott's prourokinase) and "nerve cell transplants" (Pittsburgh U's nine patient study using nerve cells derived from a rare type of cancer tumor). None of the public cast of stem cell characters mentioned, just "Layton BioScience Inc." of Atherton. Abbott (stroke article) says they will file application to market by midyear...and that their product has certain advantages over the main competition is Genentech's "Activase" according to Dr. Furlan (Medical Director of the cerebral vascular center @ Cleveland Clinic who headed the study). DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next